Levi & Korsinsky, LLP announces that a BIIB class action lawsuit has been filed on behalf of investors who purchased Biogen Inc. (BIIB) securities between June 7, 2021, and January 11, 2022.  For more on the BIIB Lawsuit please contact us today.

According to the Biogen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration (“FDA”) that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer’s disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer’s patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019, and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and those side-effects were dangerous and serious.

TO LEARN MORE ABOUT THE BIIB CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Biogen you have until April 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com